Processing

Please wait...

Settings

Settings

1. WO1991000108 - ANTIBODY-OXIDASE CONJUGATES WITH NON-SYSTEMIC SUBSTRATES

Publication Number WO/1991/000108
Publication Date 10.01.1991
International Application No. PCT/US1990/001527
International Filing Date 21.03.1990
IPC
A61K 47/48 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
48the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
CPC
A61K 47/67
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
66the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
67Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
A61K 47/6893
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6891Pre-targeting systems involving an antibody for targeting specific cells
6893clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
A61K 47/6899
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6891Pre-targeting systems involving an antibody for targeting specific cells
6899Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
B82Y 5/00
BPERFORMING OPERATIONS; TRANSPORTING
82NANOTECHNOLOGY
YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
5Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Applicants
  • BRUNSWICK CORPORATION [US/US]; One Brunswick Plaza Skokie, IL 60077, US
Inventors
  • DUNCAN, John, D.; US
  • HOFMANN, Frieder, K.; US
Agents
  • WALDRON, James, S.; Waldron & Associates 2120 L Street, N.W. Suite 200 Washington, DC 20037, US
Priority Data
374,04830.06.1989US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTIBODY-OXIDASE CONJUGATES WITH NON-SYSTEMIC SUBSTRATES
(FR) CONJUGUES D'ANTICORPS-OXYDASE A SUBSTRATS NON SYSTEMIQUES
Abstract
(EN)
Enzyme-immunoconjugates which can be used for therapeutic purposes without significant patient side effects due to their administration. The general type of enzyme-immunoconjugate is composed of any antibody or fragment thereof linked to an oxidase whose natural substrate is not normally present in the body fluids or otherwise available in the extracellular spaces of the body. The therapeutic action of such oxidases lies in their ability to produce the cytotoxic yet biologically rapidly degrading agent hydrogen peroxide. Such oxidase-immunoconjugates would be specifically targeted to the desired tissues by use of the antibody component but would not be active until such time as a substrate of exogenous source is administered to the patient, whereupon hydrogen peroxide would be produced by the enzymatic process wherever the oxidase-immunoconjugate is present.
(FR)
Immunoconjugués d'enzymes pouvant être utilisés à des fins thérapeutiques sans effets secondaires significatifs chez les patients, dus à leur administration. Le type général d'immunoconjugué d'enzymes se compose de n'importe quel anticorps ou fragment de celui-ci lié à une oxydase dont le substrat naturel n'est pas normalement présent dans les fluides biologiques ou autrement disponibles dans des espaces extracellulaires du corps. L'action thérapeutique de telles oxydases repose dans leur capacité à produire l'agent de peroxyde d'hydrogène cytotoxique mais à dégradation biologique rapide. Lesdits immunoconjugués d'oxydases auraient spécifiquement pour cibles les tissus désirés, à l'aide du composant d'anticorps, mais ne seraient actifs qu'au moment ou un substrat de source exogène est administré au patient, après quoi le peroxyde d'hydrogène serait produit par le processus enzymatique partout ou l'immunoconjugué d'oxydase est présent.
Also published as
Latest bibliographic data on file with the International Bureau